Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Common Equity (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Common Equity over the past 15 years, most recently at $1.3 million for Q2 2025.

  • Quarterly results put Common Equity at $1.3 million for Q2 2025, down 88.19% from a year ago — trailing twelve months through May 2025 was $1.3 million (down 88.19% YoY), and the annual figure for FY2025 was $1.3 million, down 88.19%.
  • Common Equity for Q2 2025 was $1.3 million at Lifecore Biomedical, Inc. \De\, down from $2.2 million in the prior quarter.
  • Over the last five years, Common Equity for LFCR hit a ceiling of $202.2 million in Q1 2021 and a floor of -$13.6 million in Q3 2023.
  • Median Common Equity over the past 5 years was $26.4 million (2023), compared with a mean of $66.4 million.
  • Biggest five-year swings in Common Equity: plummeted 117.41% in 2023 and later skyrocketed 987.19% in 2024.
  • Lifecore Biomedical, Inc. \De\'s Common Equity stood at $155.4 million in 2021, then tumbled by 54.23% to $71.1 million in 2022, then tumbled by 98.0% to $1.4 million in 2023, then skyrocketed by 987.19% to $15.4 million in 2024, then tumbled by 91.35% to $1.3 million in 2025.
  • The last three reported values for Common Equity were $1.3 million (Q2 2025), $2.2 million (Q1 2025), and $15.4 million (Q4 2024) per Business Quant data.